Skip to main content

Advertisement

SpringerLink
Log in

The association between prucalopride efficacy and constipation type

  • Original Article
  • Published:
Techniques in Coloproctology Aims and scope Submit manuscript

Abstract

Background

Prucalopride is a selective serotonin receptor agonist with prokinetic activity, indicated for women with chronic constipation in whom laxatives have failed to provide adequate relief. Data suggests an improvement in about 50 % of such patients but whether the therapeutic effect is on patients with slow transit constipation (STC) and/or obstructed defaecation syndrome (ODS), or even those with constipation-predominant irritable bowel syndrome (IBS-C) is unknown. We therefore assessed whether there is any association between prucalopride efficacy and constipation type.

Methods

All patients receiving prucalopride between June 2010 and April 2012 at our institution were identified, and data analysed following a 4-week “test” period. Patients were sub-grouped as those suffering with ODS, STC, mixed (ODS and STC) or IBS-C based on symptomatology and investigations. Subjective assessment of patient satisfaction and continuation of medication were taken as positive outcomes and analysed for each sub-type along with any side effects.

Results

Sixty-nine patients met our criteria. Data were available for 59 women (median age 46 years, range 17–79 years). Sixty-five per cent of prescriptions came from colorectal surgeons. Overall, 25 out of 59 (42 %) patients improved, according to our criteria, after the 4-week trial period. Seventeen patients (29 %) had ODS, 26 (44 %) had STC, 7 (12 %) had mixed symptoms and 9 (15 %) had IBS-C. At 4 weeks, 10 out of 17 patients (59 %) with ODS had improved compared with 4 out of 9 patients (44 %) with IBS-C, 3 out of 7 patients (43 %) with mixed symptoms and 8 out of 26 (31 %) patients with STC. The underlying disorder did not predict whether or not a patient responded to the 4-week trial period (p = 0.32). Nine patients (15 %) experienced side effects that precluded further use.

Conclusions

Patients with all categories of constipation may respond to prucalopride. A trial regime may be indicated regardless of the aetiology of the constipation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Higgins PD, Johanson JF (2004) Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 99:750–759

    Article  PubMed  Google Scholar 

  2. Peppas G, Alexiou VG, Mourtzoukou E, Falagas ME (2008) Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol 8:5

    Article  PubMed  Google Scholar 

  3. Glia A, Lindberg G (1997) Quality of life in patients with different types of functional constipation. Scand J Gastroenterol 32:1083–1089

    Article  PubMed  CAS  Google Scholar 

  4. Irvine EJ, Ferazzi S, Pare P, Thompson WG, Rance L (2002) Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 97:1986–1993

    Article  PubMed  CAS  Google Scholar 

  5. Tack J, Dubois D, Schenk F (2009) Only 27% of patients with chronic constipation are satisfied with current treatment options. Gut 58(Suppl. II):181

    Google Scholar 

  6. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130:1480–1491

    Article  PubMed  Google Scholar 

  7. Bharucha AE, Wald A, Enck P, Rao S (2006) Functional anorectal disorders. Gastroenterology 130:1510–1518

    Article  PubMed  Google Scholar 

  8. Drossman DA, Camilleri M, Mayer EA, Whitehead WE (2002) AGA technical review on irritable bowel syndrome. Gastroenterology 123:2108–2131

    Article  PubMed  Google Scholar 

  9. De Schryver AM, Andriesse GI, Samsom M, Smout AJ, Gooszen HG, Akkermans LM (2002) The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther 16:603–612

    Article  PubMed  Google Scholar 

  10. National Institute for Health and Clinical Excellence. TA211 Constipation (women)—prucalopride: guidance. 15 Dec 2010

  11. Camilleri M, Kerstens R, Rykx A, Vandeplassche L (2008) A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358:2344–2354

    Article  PubMed  CAS  Google Scholar 

  12. Quigley EM, Vandeplassche L, Kerstens R, Ausma J (2009) Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo- controlled study. Aliment Pharmacol Ther 29:315–328

    Article  PubMed  CAS  Google Scholar 

  13. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L (2009) Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 58:357–365

    Article  PubMed  CAS  Google Scholar 

  14. Attaluri A, Rao S (2006) Diagnostic and therapeutic approaches to patients with constipation. Practical Gastroenterol 30:30–47

    Google Scholar 

  15. Chey WD, Pare P, Viegas A, Ligozio G, Shetzline MA (2008) Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol 103:1217–1225

    Article  PubMed  CAS  Google Scholar 

  16. Layer P, Keller J, Loeffler H, Kreiss A (2007) Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom. Ther Clin Risk Manag 3:107–118

    Article  PubMed  CAS  Google Scholar 

  17. Evans BW, Clark WK, Moore DJ, Whorwell PJ (2007) Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev CD003960

  18. Novick J, Miner P, Krause R et al (2002) A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 16:1877–1888

    Article  PubMed  CAS  Google Scholar 

  19. US FDA public health advisory tegaserod maleate (marketed Zelnorm™). http://www.fda.gov/CDER/DRUG/advisory/tegaserod.htm. (Accessed July 2008)

  20. Bannister JJ, Davidson P, Timms JM, Gibbons C, Read NW (1987) Effect of stool size and consistency on defaecation. Gut 28:1242–1245

    Article  PubMed  CAS  Google Scholar 

  21. Bassotti G, Villanacci V, Nascimbeni R et al (2012) Increase of colonic mast cells in obstructed defaecation and their relationship with enteric glia. Dig Dis Sci 57:65–71

    Article  PubMed  CAS  Google Scholar 

  22. Bassotti G, Villanacci V, Bellomi A et al (2012) An assessment of enteric nervous system and estroprogestinic receptors in obstructed defecation associated with rectal intussusception. Neurogastroenterol Mot 24:155–161

    Article  Google Scholar 

  23. Bassotti G, Villanacci V, Nascimbeni R et al (2007) Colonic neuropathological aspects in patients with intractable constipation due to obstructed defecation. Mod Pathol 20:367–374

    Article  PubMed  Google Scholar 

  24. D’Hoore A, Penninckx F (2006) Laparoscopic ventral recto(colpo)pexy for rectal prolapse: surgical technique and outcome for 109 patients. Surg Endosc 20:1919–1923

    Article  PubMed  Google Scholar 

  25. Slawik S, Soulsby R, Carter H, Payne H, Dixon AR (2008) Laparoscopic ventral rectopexy, posterior colporrhaphy and vaginal sacrocolpopexy for the treatment of recto-genital prolapse and mechanical outlet obstruction. Colorectal Dis 10:138–143

    PubMed  CAS  Google Scholar 

  26. Collinson R, Wijffels N, Cunningham C, Lindsey I (2010) Laparoscopic ventral rectopexy for internal rectal prolapse: short-term functional results. Colorectal Dis 12:97–104

    Article  PubMed  CAS  Google Scholar 

  27. Lehur PA, Stuto A, Fantoli M et al (2008) ODS II Study Group. Outcomes of stapled transanal rectal resection versus biofeedback for the treatment of outlet obstruction associated with rectal intussusception and rectocele: a multicenter, randomized, controlled trial. Dis Colon Rectum 51:1739

    Article  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Colorectal Surgical Unit, Northern General Hospital, Sheffield, UK

    A. M. Jadav, C. M. Mcmullin, J. Smith, K. Chapple & S. R. Brown

  2. Department of Surgery, Northern General Hospital, Herries Road, Sheffield, S5 7AU, UK

    S. R. Brown

Authors
  1. A. M. Jadav
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. M. Mcmullin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Chapple
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. R. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. M. Jadav.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jadav, A.M., Mcmullin, C.M., Smith, J. et al. The association between prucalopride efficacy and constipation type. Tech Coloproctol 17, 555–559 (2013). https://doi.org/10.1007/s10151-013-1017-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10151-013-1017-8

Keywords

Search

Navigation